Amlodipine And Olmesartan Medoxomil

Diabetic Nephropathies, Hypertensive disease, multiple antihypertensive drugs likely required + 1 more

Treatment

2 FDA approvals

20 Active Studies for Amlodipine And Olmesartan Medoxomil

What is Amlodipine And Olmesartan Medoxomil

Olmesartan

The Generic name of this drug

Treatment Summary

Olmesartan is a medication used to lower high blood pressure. It belongs to a family of drugs called angiotensin II receptor blockers (ARBs) that work by blocking a protein called angiotensin II, which helps regulate blood pressure. Olmesartan can also help slow the progression of kidney damage caused by type 2 diabetes. It is generally well tolerated and can be used safely in adults and children. Olmesartan was developed by Daiichi Sankyo Pharmaceuticals and approved in 2002.

Benicar

is the brand name

Amlodipine And Olmesartan Medoxomil Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Benicar

Olmesartan

2002

340

Approved as Treatment by the FDA

Olmesartan, also called Benicar, is approved by the FDA for 2 uses which include Therapeutic procedure and Hypertensive disease .

Therapeutic procedure

Used to treat failed primary treatment in combination with Hydrochlorothiazide

Hypertensive disease

Used to treat High Blood Pressure (Hypertension) in combination with Hydrochlorothiazide

Effectiveness

How Amlodipine And Olmesartan Medoxomil Affects Patients

Olmesartan works by reducing blood pressure, decreasing aldosterone levels, and increasing the amount of sodium excreted in the body. It is important to be monitored closely by a doctor while taking olmesartan, as it may cause hypotension, especially in patients who are low on salt or volume. Those with aortic stenosis should be extra cautious, as there is a risk of decreased coronary perfusion. Olmesartan may also impair renal function and cause electrolyte imbalances. In some cases, prolonged use of olmesartan may cause severe diarrhea, weight loss, and villous atrophy

How Amlodipine And Olmesartan Medoxomil works in the body

Olmesartan is a type of drug called an angiotensin II receptor blocker (ARB). It works by preventing the protein angiotensin II from causing blood vessels to become narrow. This helps keep blood pressure lower, reduces aldosterone levels, and makes the heart pump less. Olmesartan also affects the renin-angiotensin aldosterone system (RAAS), which helps regulate the body's blood pressure, kidney, and heart. Studies have shown that blocking RAAS with ARBs can help protect the heart from further damage caused by heart failure.

When to interrupt dosage

The dosage of Amlodipine And Olmesartan Medoxomil is contingent upon the diagnosed affliction, including Diabetic Nephropathy, Hypertensive illness and Therapeutic procedure. The measure of dosage is contingent on the approach of administration (e.g. Oral or Tablet, film coated) detailed in the following table.

Condition

Dosage

Administration

Diabetic Nephropathies

40.0 mg, , 20.0 mg, 5.0 mg, 10.0 mg

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated - Oral, Tablet, coated

Hypertensive disease

40.0 mg, , 20.0 mg, 5.0 mg, 10.0 mg

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated - Oral, Tablet, coated

multiple antihypertensive drugs likely required

40.0 mg, , 20.0 mg, 5.0 mg, 10.0 mg

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated - Oral, Tablet, coated

Therapeutic procedure

40.0 mg, , 20.0 mg, 5.0 mg, 10.0 mg

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated - Oral, Tablet, coated

Warnings

Amlodipine And Olmesartan Medoxomil Contraindications

Condition

Risk Level

Notes

Type 2 Diabetes

Do Not Combine

There are 20 known major drug interactions with Amlodipine And Olmesartan Medoxomil.

Common Amlodipine And Olmesartan Medoxomil Drug Interactions

Drug Name

Risk Level

Description

Amifostine

Major

Olmesartan may increase the hypotensive activities of Amifostine.

Lithium carbonate

Major

The serum concentration of Lithium carbonate can be increased when it is combined with Olmesartan.

Lithium citrate

Major

The serum concentration of Lithium citrate can be increased when it is combined with Olmesartan.

Lithium hydroxide

Major

The serum concentration of Lithium hydroxide can be increased when it is combined with Olmesartan.

Acebutolol

Minor

Olmesartan may increase the hypotensive activities of Acebutolol.

Amlodipine And Olmesartan Medoxomil Toxicity & Overdose Risk

The most toxic dose of olmesartan in dogs was found to be greater than 1500mg/kg. Overdosing on olmesartan can cause low blood pressure, a rapid heartbeat, or a slow heartbeat. Treatment for overdose includes supportive care. Olmesartan has not been shown to be carcinogenic or affect fertility in studies, but it has been shown to cause changes to chromosomes and to induce mutations in cells in laboratory studies.

Amlodipine And Olmesartan Medoxomil Novel Uses: Which Conditions Have a Clinical Trial Featuring Amlodipine And Olmesartan Medoxomil?

19 active studies are currently being conducted to evaluate the potential of Amlodipine And Olmesartan Medoxomil in providing Therapeutic Procedures, Hypertensive Disease Treatment and the likely requirement of Multiple Antihypertensive Drugs.

Condition

Clinical Trials

Trial Phases

Hypertensive disease

27 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Phase 3

Diabetic Nephropathies

0 Actively Recruiting

Therapeutic procedure

0 Actively Recruiting

multiple antihypertensive drugs likely required

0 Actively Recruiting

Patient Q&A Section about amlodipine and olmesartan medoxomil

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Can I take olmesartan and amlodipine together?

"The combination of amlodipine and olmesartan may be used to treat high blood pressure, which puts extra strain on the heart and arteries. If left untreated, high blood pressure can lead to long-term damage to the heart and arteries."

Answered by AI

How long does amlodipine and olmesartan take to work?

"It may take a couple of weeks to start feeling the full effects of this medication. If your condition doesn't improve or gets worse (your blood pressure readings stay high or go up), let your doctor know."

Answered by AI

What are the side effects of olmesartan amlodipine?

"If you experience any of the following symptoms, you should contact your doctor immediately as they may be signs of a liver problem: dark urine, decreased urine output, itching, skin rash, large hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs, light-colored stools, muscle pain or stiffness, stomach pain, or upper right abdominal or stomach pain."

Answered by AI

What is the difference between olmesartan medoxomil and amlodipine?

"Amlodipine and olmesartan is a combination medicine used to treat high blood pressure (hypertension). Amlodipine is a calcium channel blocker and olmesartan is an angiotensin II receptor blocker (sometimes called an ARB)."

Answered by AI

Clinical Trials for Amlodipine And Olmesartan Medoxomil

Image of Miles Square Health Center Chicago in Chicago, United States.

Food is Medicine for High Blood Pressure and Obesity

Any Age
All Sexes
Chicago, IL

The goal of this clinical trial is to treat both hypertension and obesity in adults using a food is medicine framework. Participants will be randomized 1:1 to FIM+DASH or usual-care control. The 24-week trial includes a 12-week FIM+DASH intervention followed by a 12-week maintenance period and leverages existing partnerships with community-based organizations for home food delivery and culinary skill-skill building. The main questions it aims to answer are: (1) What is the effect of FIM+DASH vs. usual care control on blood pressure? (2) What is the effect of FIM+DASH vs. usual care control on DASH diet adherence (diet quality), body weight, and waist circumference? (3) How to identify factors associated with the sustainability and scalability of FIM+DASH in real-world settings?

Phase 2
Waitlist Available

Miles Square Health Center Chicago (+3 Sites)

Image of U Health in Miami, United States.

Cuffless PPG Monitor for High Blood Pressure

18+
All Sexes
Miami, FL

This study aims to validate the accuracy and reliability of blood pressure (BP) estimates obtained over 24 hours using a PPG-based chest-patch device compared to the gold standard ambulatory blood pressure monitoring (ABPM) method using an upper arm cuff-based oscillometric BP device, in both hypertensive and normotensive individuals referred by their provider to undergo a 24-hours ABPM for clinical indication. The Awake/Asleep test, which is the primary test recommended for automated wearable cuffless BP devices that are cuff-calibrated (based on the 2023 European Society of Hypertension (ESH) recommendations for the validation of cuffless blood pressure measuring devices), will be conducted in this study. The secondary aim of the study is to assess the feasibility and convenience of the PPG-based device.

Waitlist Available
Has No Placebo

U Health (+1 Sites)

Ziad Zoghby, M.D., M.B.A.

Biobeat Technologies Ltd.

Have you considered Amlodipine And Olmesartan Medoxomil clinical trials?

We made a collection of clinical trials featuring Amlodipine And Olmesartan Medoxomil, we think they might fit your search criteria.
Go to Trials
Image of Wayne Health Mobile Units in Detroit, United States.

Text Message Reminders for High Blood Pressure

18+
All Sexes
Detroit, MI

This project is part of the ACHIEVE GREATER (Addressing Cardiometabolic Health In Populations Through Early PreVEntion in the GREAT LakEs Region) Center (IRB# 100221MP2A), the purpose of which is to improve cardiometabolic health in two uniquely comparable cities: Detroit, Michigan, and Cleveland, Ohio. The ACHIEVE GREATER Center involves separate but related projects that aim to improve cardiometabolic health outcomes through better risk factor control for three chronic conditions that are of tremendous public health importance, (hypertension (HTN), heart failure, and coronary heart disease), all of which contribute significantly to premature death in Detroit and Cleveland. The present study is the prospective observational cohort component of ACHIEVE P1- EPI (Project 1) of the ACHIEVE GREATER Center and serves to characterize the population of patients with blood pressure (BP) levels above normal attending The Wayne Health Mobile Health Unit (MHU) events to better understand key factors (e.g., social determinants of health) that convey information about baseline BP levels and related clinical outcomes (e.g., follow-up clinic visits, BP control, and cardiovascular events).

Recruiting
Has No Placebo

Wayne Health Mobile Units

Steven J Korzeniewski, PhD

Have you considered Amlodipine And Olmesartan Medoxomil clinical trials?

We made a collection of clinical trials featuring Amlodipine And Olmesartan Medoxomil, we think they might fit your search criteria.
Go to Trials
Image of Northern Arizona University in Flagstaff, United States.

CardioCare Quest for High Blood Pressure

18+
All Sexes
Flagstaff, AZ

This project aims to address healthcare disparities among Navaho people diagnosed with hypertension or prehypertension through three main objectives. Firstly, it identifies and shares insights on healthcare access disparities affecting Navaho individuals experiencing nonadherence to hypertension treatment. Secondly, the proposal develops a telehealth solution based on factors identified as knowledge gaps caused by healthcare access disparities in hypertension management; we will use the factors to design a series of engaging minigames that can be incorporated into the larger CardioCare Quest. These minigames will be co-designed with end users and clinicians. Finally, the proposal conducts comprehensive qualitative and quantitative assessments of user experiences, perceptions, and challenges with CardioCare Quest.

Recruiting
Has No Placebo

Northern Arizona University (+1 Sites)

Tochukwu Ikwunne, PhD

Image of Tufts University in Boston, United States.

Food as Medicine for Cardiometabolic Health

18+
All Sexes
Boston, MA

Though the Mississippi Delta has a rich agricultural history and some of the nation's most fertile soil, residents have experienced the legacy of slavery and economic exploitation through food insecurity and poverty for generations. This project focuses on Bolivar, Washington, and Sunflower, contiguous counties in the Delta that are designated as health disparity populations. Over 65% of the 100,000 residents are Black/African American and \~30% live at or below the poverty level. Obesity rates are high and the rate of diabetes is almost double the national average. Tufts University received a grant from the National Institute of Minority Health and Health Disparities to develop, test, and evaluate a Food is Medicine program in Mississippi. The Delta Growing a Resilient, Enriching, Equitable, Nourishing food System (GREENS) Food is Medicine (FIM) Project, is a collaborative project in Bolivar, Washington, and Sunflower counties in Mississippi. The intervention involves regularly distributed fruit and vegetable produce boxes as well as nutrition education materials to the intervention group. The control group will receive produce boxes later, after they complete study activities. The project's primary goal is to improve health outcomes by creating a FIM intervention. The Delta GREENS FIM Project aims to become a model for promoting nutrition security and management of chronic conditions in varied communities nationwide.

Recruiting
Has No Placebo

Tufts University

Christina D Economos, PhD

Have you considered Amlodipine And Olmesartan Medoxomil clinical trials?

We made a collection of clinical trials featuring Amlodipine And Olmesartan Medoxomil, we think they might fit your search criteria.
Go to Trials